Pharmaforce ApS — Credit Rating and Financial Key Figures
CVR number: 26394198
Frederiksborggade 15, 1360 København K
tel: 70272747
www.pharmaforce.dk
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 4 304.74 | 4 304.74 | 4 201.68 | 3 639.95 | 3 682.48 |
| Employee benefit expenses | -2 889.06 | -2 889.06 | -3 736.19 | -3 203.72 | -3 328.50 |
| Other operating expenses | -11.63 | -9.69 | |||
| EBIT | 1 415.68 | 1 415.68 | 465.49 | 424.60 | 344.29 |
| Other financial income | 28.78 | 28.78 | 64.79 | 3.15 | 42.50 |
| Other financial expenses | -45.74 | -45.74 | -51.98 | -57.31 | -41.81 |
| Pre-tax profit | 1 398.72 | 1 398.72 | 478.30 | 370.44 | 344.98 |
| Income taxes | - 317.92 | - 317.92 | - 110.81 | -87.74 | -82.76 |
| Net earnings | 1 080.80 | 1 080.80 | 367.49 | 282.71 | 262.22 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Other receivables | 81.00 | 81.00 | 81.00 | 82.13 | 1.13 |
| Investments total | 81.00 | 81.00 | 81.00 | 82.13 | 1.13 |
| Long term receivables total | |||||
| Finished products/goods | 1 773.58 | 1 773.58 | 1 380.73 | 2 044.43 | 2 045.21 |
| Inventories total | 1 773.58 | 1 773.58 | 1 380.73 | 2 044.43 | 2 045.21 |
| Current trade debtors | 1 666.09 | 1 666.09 | 1 553.09 | 2 513.41 | 1 050.81 |
| Current amounts owed by group member comp. | 68.75 | 68.75 | 61.14 | 124.63 | 131.64 |
| Current other receivables | 1 999.44 | 1 999.44 | 2 700.91 | 51.13 | 32.03 |
| Short term receivables total | 3 734.27 | 3 734.27 | 4 315.14 | 2 689.16 | 1 214.47 |
| Cash and bank deposits | 550.41 | 550.41 | 999.37 | 818.91 | 1 525.79 |
| Cash and cash equivalents | 550.41 | 550.41 | 999.37 | 818.91 | 1 525.79 |
| Balance sheet total (assets) | 6 139.27 | 6 139.27 | 6 776.24 | 5 634.63 | 4 786.60 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 125.00 | 125.00 | 125.00 | 125.00 | 125.00 |
| Shares repurchased | 300.00 | 200.00 | 500.00 | ||
| Retained earnings | 1 302.08 | 1 302.08 | 2 082.88 | 2 250.37 | 2 033.08 |
| Profit of the financial year | 1 080.80 | 1 080.80 | 367.49 | 282.71 | 262.22 |
| Shareholders equity total | 2 507.88 | 2 507.88 | 2 875.37 | 2 858.08 | 2 920.30 |
| Non-current loans from credit institutions | 303.55 | 303.55 | 144.02 | ||
| Non-current liabilities total | 303.55 | 303.55 | 144.02 | ||
| Current loans from credit institutions | 1 808.32 | 144.08 | |||
| Advances received | 224.61 | 224.61 | |||
| Current trade creditors | 1 566.94 | 1 566.94 | 1 151.80 | 2 030.56 | 1 088.55 |
| Current owed to participating | 39.87 | 39.87 | 26.73 | 27.86 | 27.86 |
| Short-term deferred tax liabilities | 331.91 | 331.91 | 115.58 | 91.60 | 89.14 |
| Other non-interest bearing current liabilities | 1 164.50 | 1 164.50 | 654.43 | 482.47 | 660.76 |
| Current liabilities total | 3 327.83 | 3 327.83 | 3 756.85 | 2 776.55 | 1 866.31 |
| Balance sheet total (liabilities) | 6 139.27 | 6 139.27 | 6 776.24 | 5 634.63 | 4 786.60 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.